Women with uncommon form of ovarian cancer offered hope with new drugs
Tumours shrank or stopped growing in almost one in three women (31 per cent) with low-grade serous ovarian cancer, which does not respond well to chemotherapy, when taking a combination of avutometinib and defactinib. The drugs work by blocking signals that encourage cancer cells to grow.